AR and breast carcinoma: Whilst BQ overexpression enhanced both NHEJ and homologous recombination (HR) activities, we showed that upon AR inhibition with bicalutamide (BIC), NHEJ was more significantly reduced (>50%) than HR (~50%) (Figure 6E–H), suggesting the dominance of NHEJ in our breast cancer model.